WO2003044000A1 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 - Google Patents
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 Download PDFInfo
- Publication number
- WO2003044000A1 WO2003044000A1 PCT/SE2002/002139 SE0202139W WO03044000A1 WO 2003044000 A1 WO2003044000 A1 WO 2003044000A1 SE 0202139 W SE0202139 W SE 0202139W WO 03044000 A1 WO03044000 A1 WO 03044000A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thiadiazol
- chloro
- methyl
- amino
- sulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- Adrenalectomy attenuates the effect of fasting to increase both food intake and hypothalamic neuropeptide Y expression. This supports the role of glucocorticoids in promoting food intake and suggests that inhibition of 11 ⁇ HSDl in the brain might increase satiety and therefore reduce food intake (Woods, S.C et al. (1998) Science, 280: 1378-1383).
- R 5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n- propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl;
- R 3 and R 4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached mo ⁇ holinyl;
- R 5 O wherein R 5 is acetyl, benzoyl, benzyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3- pyridinyl, 2,2,2-trifluoroethyl.
- C ⁇ - 6 -acyl in the compound of formula (I) according to the present application may be saturated or unsaturated and is preferably C ⁇ - 4 -acyl.
- exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, butenoyl (e.g. 3-butenoyl), hexenoyl (e.g. 5-hexenoyl).
- C ⁇ . 6 -acyl all subgroups thereof are contemplated such as C ⁇ . 5 -acyl, C ⁇ _ 4 -acyl, C ⁇ _ 3 -acyl, C ⁇ .
- compositions according to the present invention may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical or sterile parenteral solutions or suspensions.
- Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, traganath or polyvinyl-pyrrolidone; fillers e.g. lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant e.g.
- Oral liquid preparations may be in the form of e.g. aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, e.g. sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents e.g.
- the calculation of the Kj values for the inhibitors was performed by use of Activity Base.
- the IC 5 o is measured experimentally in an assay wherein the decrease of the turnover of cortisone to cortisol is dependent on the inhibition potential of each substance.
- the Ki values of the compounds of the present invention for the 11- ⁇ -HSDl enzyme lie typically between about 10 nM and about 10 ⁇ M.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002353717A AU2002353717B2 (en) | 2001-11-22 | 2002-11-22 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
JP2003545637A JP2005509676A (ja) | 2001-11-22 | 2002-11-22 | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1型のインヒビター |
EP02789089A EP1461327A1 (en) | 2001-11-22 | 2002-11-22 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
YUP-442/04A RS44204A (en) | 2001-11-22 | 2002-11-22 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
CA002466491A CA2466491A1 (en) | 2001-11-22 | 2002-11-22 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
MXPA04004842A MXPA04004842A (es) | 2001-11-22 | 2002-11-22 | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. |
IL16063002A IL160630A0 (en) | 2001-11-22 | 2002-11-22 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
BR0214342-9A BR0214342A (pt) | 2001-11-22 | 2002-11-22 | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 |
EA200400708A EA200400708A1 (ru) | 2001-11-22 | 2002-11-22 | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 |
NO20042161A NO20042161L (no) | 2001-11-22 | 2004-05-25 | Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0103913-0 | 2001-11-22 | ||
SE0103913 | 2001-11-22 | ||
SE0104051-8 | 2001-11-30 | ||
SE0104051 | 2001-11-30 | ||
US34846802P | 2002-01-14 | 2002-01-14 | |
US60/348,468 | 2002-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003044000A1 true WO2003044000A1 (en) | 2003-05-30 |
Family
ID=27354771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2002/002139 WO2003044000A1 (en) | 2001-11-22 | 2002-11-22 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1461327A1 (pt) |
JP (1) | JP2005509676A (pt) |
KR (1) | KR20050044578A (pt) |
CN (1) | CN1649855A (pt) |
AU (1) | AU2002353717B2 (pt) |
BR (1) | BR0214342A (pt) |
CA (1) | CA2466491A1 (pt) |
IL (1) | IL160630A0 (pt) |
MX (1) | MXPA04004842A (pt) |
NO (1) | NO20042161L (pt) |
PL (1) | PL370447A1 (pt) |
WO (1) | WO2003044000A1 (pt) |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004103980A1 (en) * | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
WO2004113310A1 (en) * | 2003-06-25 | 2004-12-29 | Biovitrum Ab | Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing |
US6849636B2 (en) | 2002-12-20 | 2005-02-01 | Merck & Co., Inc. | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
WO2005042513A1 (en) * | 2003-10-23 | 2005-05-12 | Sterix Limited | Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase |
WO2005103023A1 (en) * | 2004-04-20 | 2005-11-03 | Sterix Limited | Phenylsulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase inhibitors |
WO2006048331A1 (en) * | 2004-11-08 | 2006-05-11 | Evotec Ag | 11β-HSD1 INHIBITORS |
WO2006050908A1 (en) * | 2004-11-08 | 2006-05-18 | Evotec Ag | Inhibitors of 11βετα-hydroxy steroid dehydrogenase type 1 (11beta-hsd1) |
US7074788B2 (en) | 2001-11-22 | 2006-07-11 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
US7173030B2 (en) | 2003-05-21 | 2007-02-06 | Biovitrum Ab | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
WO2007025892A1 (en) | 2005-08-31 | 2007-03-08 | F. Hoffmann-La Roche Ag | 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 |
US7230020B2 (en) | 2003-10-23 | 2007-06-12 | Sterix Limited | 11β-hydroxysteroid dehydrogenase inhibitors |
US7253196B2 (en) | 2004-05-24 | 2007-08-07 | Amgen, Inc. | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
WO2007128761A2 (de) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Verwendungen von dpp iv inhibitoren |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
US7345058B2 (en) | 2005-04-05 | 2008-03-18 | Hoffmann-La Roche Inc. | Pyrazoles |
JP2008515826A (ja) * | 2004-10-04 | 2008-05-15 | エフ.ホフマン−ラ ロシュ アーゲー | 糖尿病のための11−β阻害剤としてのアルキルピリジン |
DE102007005045A1 (de) | 2007-01-26 | 2008-08-07 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
EP2036548A1 (en) | 2003-09-22 | 2009-03-18 | onepharm Research & Development GmbH | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
US7632838B2 (en) | 2006-02-07 | 2009-12-15 | Wyeth | 11-beta HSD1 inhibitors |
US7645773B2 (en) | 2006-01-18 | 2010-01-12 | Hoffmann-La Roche Inc. | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US7759339B2 (en) | 2005-03-31 | 2010-07-20 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8071631B2 (en) * | 2006-08-16 | 2011-12-06 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Small molecule inhibitors of kynurenine-3-monooxygenase |
WO2011128304A3 (de) * | 2010-04-16 | 2011-12-08 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
JP5147109B2 (ja) * | 2005-06-07 | 2013-02-20 | 塩野義製薬株式会社 | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8541592B2 (en) | 2005-11-22 | 2013-09-24 | Amgen Inc. | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 |
US8686011B2 (en) | 2004-05-24 | 2014-04-01 | Amgen Inc. | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
US8710237B2 (en) | 2006-08-16 | 2014-04-29 | The J. David Gladstone Institute | Small molecule inhibitors of kynurenine-3-monooxygenase |
US9067922B2 (en) | 2013-04-19 | 2015-06-30 | Pfizer Limited | Chemical compounds |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
US11492346B2 (en) | 2019-06-18 | 2022-11-08 | Pfizer Inc. | Benzisoxazole sulfonamide derivatives |
US11911372B2 (en) | 2018-06-28 | 2024-02-27 | Ctxt Pty Ltd | Compounds |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2624831A1 (en) * | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1053085A (pt) * | 1964-03-26 | |||
GB822947A (en) * | 1957-01-25 | 1959-11-04 | Smith & Nephew | Improvements in and relating to sulphonamides |
GB839316A (en) * | 1957-12-10 | 1960-06-29 | Bayer Ag | 5-arylsulphonamido-3-substituted 1,2,4-thiadiazole derivatives |
GB858189A (en) * | 1958-09-12 | 1961-01-11 | Bayer Ag | 5-arylsulphonamido-3-substituted-1,2,4-thiadiazole derivatives |
US3332942A (en) * | 1962-11-02 | 1967-07-25 | White Lab Inc | Substituted thiadiazoles |
EP0749964A1 (en) * | 1995-06-22 | 1996-12-27 | Zeneca Limited | N-Heterocyclyl biphenyl sulfonamides |
WO1999002502A2 (en) * | 1997-07-11 | 1999-01-21 | Smithkline Beecham Plc | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
WO2001054691A1 (en) * | 2000-01-26 | 2001-08-02 | Nicox, S.A. | Nitrate salts of antimicrobial agents |
WO2001090090A1 (en) * | 2000-05-22 | 2001-11-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
-
2002
- 2002-11-22 PL PL02370447A patent/PL370447A1/xx not_active Application Discontinuation
- 2002-11-22 CA CA002466491A patent/CA2466491A1/en not_active Abandoned
- 2002-11-22 CN CNA028202805A patent/CN1649855A/zh active Pending
- 2002-11-22 BR BR0214342-9A patent/BR0214342A/pt not_active IP Right Cessation
- 2002-11-22 EP EP02789089A patent/EP1461327A1/en not_active Withdrawn
- 2002-11-22 WO PCT/SE2002/002139 patent/WO2003044000A1/en active Application Filing
- 2002-11-22 AU AU2002353717A patent/AU2002353717B2/en not_active Ceased
- 2002-11-22 IL IL16063002A patent/IL160630A0/xx unknown
- 2002-11-22 MX MXPA04004842A patent/MXPA04004842A/es active IP Right Grant
- 2002-11-22 KR KR1020047007802A patent/KR20050044578A/ko not_active Application Discontinuation
- 2002-11-22 JP JP2003545637A patent/JP2005509676A/ja not_active Withdrawn
-
2004
- 2004-05-25 NO NO20042161A patent/NO20042161L/no unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB822947A (en) * | 1957-01-25 | 1959-11-04 | Smith & Nephew | Improvements in and relating to sulphonamides |
GB839316A (en) * | 1957-12-10 | 1960-06-29 | Bayer Ag | 5-arylsulphonamido-3-substituted 1,2,4-thiadiazole derivatives |
GB858189A (en) * | 1958-09-12 | 1961-01-11 | Bayer Ag | 5-arylsulphonamido-3-substituted-1,2,4-thiadiazole derivatives |
US3332942A (en) * | 1962-11-02 | 1967-07-25 | White Lab Inc | Substituted thiadiazoles |
GB1053085A (pt) * | 1964-03-26 | |||
EP0749964A1 (en) * | 1995-06-22 | 1996-12-27 | Zeneca Limited | N-Heterocyclyl biphenyl sulfonamides |
WO1999002502A2 (en) * | 1997-07-11 | 1999-01-21 | Smithkline Beecham Plc | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
WO2001054691A1 (en) * | 2000-01-26 | 2001-08-02 | Nicox, S.A. | Nitrate salts of antimicrobial agents |
WO2001090090A1 (en) * | 2000-05-22 | 2001-11-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
Non-Patent Citations (7)
Title |
---|
DATABASE CAPLUS [online] BURDULIENE D. ET AL.: "Synthesis and antiviral activity of N-(p-(R-sulfamoyl)phenyl)succinamic acids and their 2-amino-2-thiazoline salts", XP002962569, accession no. STN Database accession no. 1998:231998 * |
DATABASE CAPLUS [online] KIVMAN G. ET AL.: "Penetration of sulfanilamides into inflammatory foci", XP002962568, accession no. STN Database accession no. 1982:484681 * |
DATABASE REGISTRY [online] 8 October 2001 (2001-10-08), "2-Naphthalenesulfonamide, N-(5-(4-pyridinyl)-1,3,4-thiadiazol-2-yl)", XP002978826, accession no. STN * |
DATABASE REGISTRY [online] 8 October 2001 (2001-10-08), "Benzenesulfonamide, N-(5-(4-pyridinyl)-1,3,4-thiadiazol-2-yl)", XP002978827, accession no. STN * |
DATABASE REGISTRY [online] MERCK & CO., INC., USA; 1999, "Sulfamethiozole", XP002962106, Database accession no. 144-82-1 * |
KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 16, no. 6, 1982, pages 665 - 667 * |
KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 31, no. 9, 1997, pages 24 - 26 * |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074788B2 (en) | 2001-11-22 | 2006-07-11 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
US6849636B2 (en) | 2002-12-20 | 2005-02-01 | Merck & Co., Inc. | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
US7504402B2 (en) | 2002-12-20 | 2009-03-17 | Merck & Co., Inc. | Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 |
WO2004103980A1 (en) * | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
US7173030B2 (en) | 2003-05-21 | 2007-02-06 | Biovitrum Ab | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
WO2004113310A1 (en) * | 2003-06-25 | 2004-12-29 | Biovitrum Ab | Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing |
EP2036548A1 (en) | 2003-09-22 | 2009-03-18 | onepharm Research & Development GmbH | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
US7230020B2 (en) | 2003-10-23 | 2007-06-12 | Sterix Limited | 11β-hydroxysteroid dehydrogenase inhibitors |
WO2005042513A1 (en) * | 2003-10-23 | 2005-05-12 | Sterix Limited | Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
WO2005103023A1 (en) * | 2004-04-20 | 2005-11-03 | Sterix Limited | Phenylsulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase inhibitors |
US8686011B2 (en) | 2004-05-24 | 2014-04-01 | Amgen Inc. | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
US7253196B2 (en) | 2004-05-24 | 2007-08-07 | Amgen, Inc. | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
US7807700B2 (en) | 2004-05-24 | 2010-10-05 | Amgen Inc. | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
JP2008515826A (ja) * | 2004-10-04 | 2008-05-15 | エフ.ホフマン−ラ ロシュ アーゲー | 糖尿病のための11−β阻害剤としてのアルキルピリジン |
JP2011157373A (ja) * | 2004-10-04 | 2011-08-18 | F Hoffmann La Roche Ag | 糖尿病のための11−β阻害剤としてのアルキルピリジン |
EP1659113A1 (en) * | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
WO2006048331A1 (en) * | 2004-11-08 | 2006-05-11 | Evotec Ag | 11β-HSD1 INHIBITORS |
WO2006050908A1 (en) * | 2004-11-08 | 2006-05-18 | Evotec Ag | Inhibitors of 11βετα-hydroxy steroid dehydrogenase type 1 (11beta-hsd1) |
EP1666467A1 (en) * | 2004-11-08 | 2006-06-07 | Evotec AG | 11Beta-HSD1 Inhibitors |
US7759339B2 (en) | 2005-03-31 | 2010-07-20 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
US7345058B2 (en) | 2005-04-05 | 2008-03-18 | Hoffmann-La Roche Inc. | Pyrazoles |
JP5147109B2 (ja) * | 2005-06-07 | 2013-02-20 | 塩野義製薬株式会社 | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
WO2007025892A1 (en) | 2005-08-31 | 2007-03-08 | F. Hoffmann-La Roche Ag | 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 |
US8541592B2 (en) | 2005-11-22 | 2013-09-24 | Amgen Inc. | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 |
US7645773B2 (en) | 2006-01-18 | 2010-01-12 | Hoffmann-La Roche Inc. | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase |
US7632838B2 (en) | 2006-02-07 | 2009-12-15 | Wyeth | 11-beta HSD1 inhibitors |
EP2351568A2 (de) | 2006-05-04 | 2011-08-03 | Boehringer Ingelheim International GmbH | Verwendungen von dpp iv Inhibitoren |
WO2007128761A2 (de) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Verwendungen von dpp iv inhibitoren |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
EP2420494A1 (en) * | 2006-08-16 | 2012-02-22 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase |
US8071631B2 (en) * | 2006-08-16 | 2011-12-06 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Small molecule inhibitors of kynurenine-3-monooxygenase |
US8466182B2 (en) | 2006-08-16 | 2013-06-18 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Small molecule inhibitors of kynurenine-3-monooxygenase |
US8710237B2 (en) | 2006-08-16 | 2014-04-29 | The J. David Gladstone Institute | Small molecule inhibitors of kynurenine-3-monooxygenase |
DE102007005045A1 (de) | 2007-01-26 | 2008-08-07 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
JP2015187118A (ja) * | 2010-04-16 | 2015-10-29 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 有害生物防除薬としての新規な複素環化合物 |
US9339032B2 (en) | 2010-04-16 | 2016-05-17 | Bayer Intellectual Property Gmbh | Heterocyclic compounds as pesticides |
US8664229B2 (en) | 2010-04-16 | 2014-03-04 | Bayer Cropscience Ag | Heterocyclic compounds as pesticides |
JP2013525288A (ja) * | 2010-04-16 | 2013-06-20 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 有害生物防除薬としての新規な複素環化合物 |
WO2011128304A3 (de) * | 2010-04-16 | 2011-12-08 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9067922B2 (en) | 2013-04-19 | 2015-06-30 | Pfizer Limited | Chemical compounds |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
WO2017182464A1 (en) | 2016-04-19 | 2017-10-26 | Cidqo 2012, S.L. | New aza- tetracyclo derivatives |
US11911372B2 (en) | 2018-06-28 | 2024-02-27 | Ctxt Pty Ltd | Compounds |
US11492346B2 (en) | 2019-06-18 | 2022-11-08 | Pfizer Inc. | Benzisoxazole sulfonamide derivatives |
Also Published As
Publication number | Publication date |
---|---|
BR0214342A (pt) | 2004-09-14 |
CA2466491A1 (en) | 2003-05-30 |
CN1649855A (zh) | 2005-08-03 |
NO20042161L (no) | 2004-08-17 |
EP1461327A1 (en) | 2004-09-29 |
IL160630A0 (en) | 2004-07-25 |
JP2005509676A (ja) | 2005-04-14 |
AU2002353717B2 (en) | 2006-08-03 |
MXPA04004842A (es) | 2004-08-02 |
PL370447A1 (en) | 2005-05-30 |
KR20050044578A (ko) | 2005-05-12 |
AU2002353717A1 (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1461325B1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
WO2003044000A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
EP1461333A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
US7125900B2 (en) | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | |
US7671051B2 (en) | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | |
US7074788B2 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
US20030130279A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2007205749B2 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2001264456B2 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2001260932B2 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2001264456A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2001260932A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-442/04 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004/01311 Country of ref document: ZA Ref document number: 200401311 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 160630 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003545637 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028202805 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 532339 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002353717 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2466491 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1099/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/004842 Country of ref document: MX Ref document number: 1020047007802 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200400708 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002789089 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002789089 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-500355 Country of ref document: PH |